TY - JOUR
T1 - Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia
AU - Drusano, George L.
AU - Corrado, Michael L.
AU - Girardi, Gino
AU - Ellis-Grosse, Evelyn J.
AU - Wunderink, Richard G.
AU - Donnelly, Helen
AU - Leeper, Kenneth V.
AU - Brown, Mona
AU - Malek, Tasnova
AU - Hite, Robert Duncan
AU - Ferrari, Michelle
AU - Djureinovic, Danijela
AU - Kollef, Marin H.
AU - Mayfield, Lisa
AU - Doyle, Ann
AU - Chastre, Jean
AU - Combes, Alain
AU - Walsh, Thomas J.
AU - Dorizas, Krisztina
AU - Alnuaimat, Hassan
AU - Morgan, Brooks Edward
AU - Rello, Jordi
AU - Torre, Cristopher Alan Mazo
AU - Jones, Ronald N.
AU - Flamm, Robert K.
AU - Woosley, Leah
AU - Ambrose, Paul G.
AU - Bhavnani, Sujata
AU - Rubino, Christopher M.
AU - Bulik, Catharine C.
AU - Louie, Arnold
AU - Vicchiarelli, Michael
AU - Berman, Colleen
N1 - Publisher Copyright:
Copyright © 2017 American Society for Microbiology. All Rights Reserved.
PY - 2018/1
Y1 - 2018/1
N2 - Ventilator-associated bacterial pneumonia (VABP) is a difficult therapeutic problem. Considerable controversy exists regarding the optimal chemotherapy for this entity. The recent guidelines of the Infectious Diseases Society of America and the American Thoracic Society recommend a 7-day therapeutic course for VABP based on the balance of no negative impact on all-cause mortality, less resistance emergence, and fewer antibiotic treatment days, counterbalanced with a higher relapse rate for patients whose pathogen is a nonfermenter. The bacterial burden causing an infection has a substantial impact on treatment outcome and resistance selection. We describe the baseline bronchoalveolar lavage (BAL) fluid burden of organisms in suspected VABP patients screened for inclusion in a clinical trial. We measured the urea concentrations in plasma and BAL fluid to provide an index of the dilution of the bacterial and drug concentrations in the lung epithelial lining fluid introduced by the BAL procedure. We were then able to calculate the true bacterial burden as the diluted colony count times the dilution factor. The median dilution factor was 28.7, with the interquartile range (IQR) being 11.9 to 53.2. Median dilution factor-corrected colony counts were 6.18 log 10 (CFU/ml) [IQR, 5.43 to 6.46 log 10 (CFU/ml)]. In a subset of patients, repeat BAL on day 5 showed a good stability of the dilution factor. We previously showed that large bacterial burdens reduce or stop bacterial killing by granulocytes.
AB - Ventilator-associated bacterial pneumonia (VABP) is a difficult therapeutic problem. Considerable controversy exists regarding the optimal chemotherapy for this entity. The recent guidelines of the Infectious Diseases Society of America and the American Thoracic Society recommend a 7-day therapeutic course for VABP based on the balance of no negative impact on all-cause mortality, less resistance emergence, and fewer antibiotic treatment days, counterbalanced with a higher relapse rate for patients whose pathogen is a nonfermenter. The bacterial burden causing an infection has a substantial impact on treatment outcome and resistance selection. We describe the baseline bronchoalveolar lavage (BAL) fluid burden of organisms in suspected VABP patients screened for inclusion in a clinical trial. We measured the urea concentrations in plasma and BAL fluid to provide an index of the dilution of the bacterial and drug concentrations in the lung epithelial lining fluid introduced by the BAL procedure. We were then able to calculate the true bacterial burden as the diluted colony count times the dilution factor. The median dilution factor was 28.7, with the interquartile range (IQR) being 11.9 to 53.2. Median dilution factor-corrected colony counts were 6.18 log 10 (CFU/ml) [IQR, 5.43 to 6.46 log 10 (CFU/ml)]. In a subset of patients, repeat BAL on day 5 showed a good stability of the dilution factor. We previously showed that large bacterial burdens reduce or stop bacterial killing by granulocytes.
KW - Bacterial burden
KW - Bronchoalveolar lavage
KW - Ventilator-associated bacterial pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85039799376&partnerID=8YFLogxK
U2 - 10.1128/AAC.01323-17
DO - 10.1128/AAC.01323-17
M3 - Article
C2 - 29038277
AN - SCOPUS:85039799376
SN - 0066-4804
VL - 62
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 1
M1 - e01323
ER -